Related Experiment Video
Updated: Apr 6, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
2.7K
Tenofovir induced lichenoid drug eruption
Mrinal Gupta1, Heena Gupta1, Anish Gupta2
1Sudhaa Skin Centre, Jammu, Jammu and Kashmir, India.
Avicenna Journal of Medicine
|August 1, 2015
Summary
Tenofovir, a nucleotide reverse transcriptase inhibitor, rarely causes skin issues. This report details a rare case of tenofovir-induced lichenoid drug eruption in an HIV patient, resolving after drug discontinuation.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Cutaneous adverse reactions are frequent in anti-retroviral therapy.
- Tenofovir, a nucleotide reverse transcriptase inhibitor, commonly causes systemic side effects but rarely cutaneous reactions.
- Lichenoid drug eruptions are a known adverse effect of various medications.
Observation:
- A 54-year-old human immunodeficiency virus (HIV) positive male developed a generalized lichenoid eruption.
- The eruption appeared six weeks after initiating tenofovir therapy.
- Skin symptoms resolved completely upon discontinuing tenofovir.
Findings:
- This case highlights a rare instance of tenofovir-induced lichenoid drug eruption.
- Only one prior case of this specific adverse reaction to tenofovir has been documented.
- The clinical presentation and resolution pattern strongly suggest a causal link between tenofovir and the eruption.
Implications:
- Clinicians should consider tenofovir as a potential cause of lichenoid drug eruptions in HIV patients.
- Early recognition and drug cessation can lead to complete resolution of this rare cutaneous adverse effect.
- Further pharmacovigilance is needed to fully understand the cutaneous safety profile of tenofovir.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
149
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
149
01:01Hypersensitivity Reactions: Cytolytic Reactions
135
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
135
01:27Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K
01:16Drug toxicity: Idiosyncratic Reactions
171
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
171
01:19Hypersensitivity Reactions: Immune-Complex Reactions
167
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
167
01:29Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
206
Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
206